The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma
Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2021/9632427 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566344206254080 |
|---|---|
| author | Eko A. Pangarsa Ridho M. Naibaho Vina Yunarvika Budi Setiawan Damai Santosa Catharina Suharti |
| author_facet | Eko A. Pangarsa Ridho M. Naibaho Vina Yunarvika Budi Setiawan Damai Santosa Catharina Suharti |
| author_sort | Eko A. Pangarsa |
| collection | DOAJ |
| description | Up to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin’s lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR-ESHAP) chemotherapy. The ASCT went well without significant complications. This case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript. |
| format | Article |
| id | doaj-art-6fcc0b7d3d9f405d84deba51ded5dacc |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-6fcc0b7d3d9f405d84deba51ded5dacc2025-02-03T01:04:25ZengWileyCase Reports in Hematology2090-65792021-01-01202110.1155/2021/9632427The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s LymphomaEko A. Pangarsa0Ridho M. Naibaho1Vina Yunarvika2Budi Setiawan3Damai Santosa4Catharina Suharti5Subdivion of Hematology and Medical OncologyTrainee in Hematology and Medical OncologySubdivion of Hematology and Medical OncologySubdivion of Hematology and Medical OncologySubdivion of Hematology and Medical OncologySubdivion of Hematology and Medical OncologyUp to 20–40% of patients with Hodgkin’s lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin’s lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR-ESHAP) chemotherapy. The ASCT went well without significant complications. This case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript.http://dx.doi.org/10.1155/2021/9632427 |
| spellingShingle | Eko A. Pangarsa Ridho M. Naibaho Vina Yunarvika Budi Setiawan Damai Santosa Catharina Suharti The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma Case Reports in Hematology |
| title | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma |
| title_full | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma |
| title_fullStr | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma |
| title_full_unstemmed | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma |
| title_short | The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin’s Lymphoma |
| title_sort | use of etoposide ara cytarabine and melphalan eam conditioning chemotherapy in autologous stem cell transplantation asct for a patient with relapsed hodgkin s lymphoma |
| url | http://dx.doi.org/10.1155/2021/9632427 |
| work_keys_str_mv | AT ekoapangarsa theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT ridhomnaibaho theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT vinayunarvika theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT budisetiawan theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT damaisantosa theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT catharinasuharti theuseofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT ekoapangarsa useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT ridhomnaibaho useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT vinayunarvika useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT budisetiawan useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT damaisantosa useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma AT catharinasuharti useofetoposidearacytarabineandmelphalaneamconditioningchemotherapyinautologousstemcelltransplantationasctforapatientwithrelapsedhodgkinslymphoma |